Valiant Laboratories Limited has informed the Exchange about change in Management
VALIANTLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
At the 4th Annual General Meeting on September 25, 2025, shareholders approved three key changes. Mr. Santosh Vora (Managing Director) was re-appointed after retiring by rotation. Mr. Paresh Shah's designation was changed from Executive Director & CFO to Whole-Time Director & CFO, with a 5-year term running from September 25, 2025 to September 24, 2030. M/s. Mehta & Mehta, Practicing Company Secretaries, were appointed as Secretarial Auditors for five years (FY 2025-26 to FY 2029-30). The filing also confirms that both directors are not debarred from accessing capital markets by SEBI or any other authority. The disclosure notes that Mr. Santosh Vora's father, Mr. Shantilal Vora, is a Non-Executive Director on the board, indicating a promoter-family presence in management.
These are largely routine governance items — an MD re-appointment, an internal title change for the CFO, and a new secretarial auditor. No resignations, exits, or governance red flags are involved, so the announcement is likely neutral for the stock with no material impact on shareholders.